Company Filing History:
Years Active: 2024-2025
Title: Elane Fishilevich: Innovator in RNAi Therapeutics
Introduction
Elane Fishilevich is a notable inventor based in Rochester, MA (US), recognized for his contributions to the field of RNA interference (RNAi) therapeutics. With a total of three patents to his name, Fishilevich has made significant strides in developing innovative solutions for various C3-associated disorders.
Latest Patents
Fishilevich's latest patents focus on "Complement component C3 iRNA compositions and methods of use thereof." This invention relates to RNAi agents, specifically double-stranded RNA (dsRNA) agents, that target the complement component C3 gene (C3). The invention outlines methods for using these RNAi agents to inhibit the expression of the C3 gene. Furthermore, it provides approaches for preventing and treating several C3-associated disorders, including cold agglutinin disease (CAD), warm autoimmune hemolytic anemia, paroxysmal nocturnal hemoglobinuria (PNH), lupus nephritis (LN), bullous pemphigoid, and various forms of pemphigus, such as Pemphigus vulgaris (PV) and Pemphigus foliaceus (PF), as well as C3 glomerulopathy.
Career Highlights
Elane Fishilevich is currently employed at Alnylam Pharmaceuticals, Inc., where he continues to advance his research in RNAi technologies. His work has positioned him as a key figure in the development of therapeutic strategies targeting complement component C3.
Collaborations
Fishilevich collaborates with esteemed colleagues, including James D McIninch and Kristina Yucius, who contribute to the innovative research environment at Alnylam Pharmaceuticals.
Conclusion
Elane Fishilevich's work in RNAi therapeutics exemplifies the impact of innovative research on the treatment of complex disorders. His patents and collaborations highlight the importance of continued advancements in medical science.